Patents by Inventor Zili Xiao

Zili Xiao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20240109888
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: July 6, 2023
    Publication date: April 4, 2024
    Inventors: Guanglin Luo, Jie Chen, Carolyn Diane Dzierba, David B. Frennesson, Junqing Guo, Amy C. Hart, Xirui Hu, Michael E. Mertzman, Matthew Reiser Patton, Jianliang Shi, Steven H. Spergel, Brian Lee Venables, Yong-Jin Wu, Zili Xiao, Michael G. Yang
  • Substituted heterocyclic compounds
    Patent number: 11866414
    Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
    Type: Grant
    Filed: May 13, 2022
    Date of Patent: January 9, 2024
    Assignee: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Steven H. Spergel, Ryan M. Moslin, Michael Edward Mertzman, Zili Xiao
  • SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS
    Publication number: 20240002364
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: September 5, 2023
    Publication date: January 4, 2024
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: CHUNJIAN LIU, MICHAEL G. YANG, ZILI XIAO, LING CHEN, RYAN M. MOSLIN, JOHN S. TOKARSKI, DAVID S. WEINSTEIN, STEPHEN T. WROBLESKI
  • Sulfone pyridine alkyl amide-substituted heteroaryl compounds
    Patent number: 11787779
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: April 28, 2021
    Date of Patent: October 17, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chunjian Liu, Michael G. Yang, Zili Xiao, Ling Chen, Ryan M. Moslin, John S. Tokarski, David S. Weinstein, Stephen T. Wrobleski
  • Triazolopyridinyl compounds as kinase inhibitors
    Patent number: 11767322
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Grant
    Filed: October 18, 2021
    Date of Patent: September 26, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Guanglin Luo, Jie Chen, Carolyn Diane Dzierba, David B. Frennesson, Junqing Guo, Amy C. Hart, Xirui Hu, Michael C. Mertzman, Matthew Reiser Patton, Jianliang Shi, Steven H. Spergel, Brian Lee Venables, Yong-Jin Wu, Zili Xiao, Michael G. Yang
  • Substituted bicyclic compounds
    Patent number: 11701373
    Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Grant
    Filed: May 4, 2021
    Date of Patent: July 18, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, T. G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
  • IMIDAZOPYRIDAZINE COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20230183242
    Abstract: Compounds having the following formula I: or a stereoisomer or a pharmaceutically-acceptable salt thereof, wherein all substituents are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN? by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: March 4, 2020
    Publication date: June 15, 2023
    Inventors: David R. Tortolani, Zheming Ruan, Michael G. Yang, Zili Xiao
  • AMIDE-DISUBSTITUTED PYRIDINE OR PYRIDAZINE COMPOUNDS
    Publication number: 20230150979
    Abstract: Compounds having the following formula (I): (Formula (I)) or a stereoisomer or pharmaceutically-acceptable salt thereof, are useful in the modulation of IL-12, IL-23 and/or IFNa, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: January 28, 2020
    Publication date: May 18, 2023
    Inventors: Trevor C. Sherwood, Michael G. Yang, John L. Gilmore, Yanlei Zhang, Zili Xiao, Qingjie Liu
  • Heterocyclic compounds comprising pyridine useful as modulators of IL-12, IL-23 and/or IFN? responses
    Patent number: 11597721
    Abstract: Compounds having the following formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: March 7, 2023
    Assignee: Bristol-Myers Squibb Company
    Inventors: Zili Xiao, Michael G. Yang, Chunjian C. Liu, Trevor C. Sherwood, John L. Gilmore, David S. Weinstein
  • SUBSTITUTED HETEROCYCLIC COMPOUNDS
    Publication number: 20220411384
    Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
    Type: Application
    Filed: May 13, 2022
    Publication date: December 29, 2022
    Inventors: Steven H. Spergel, Ryan M. Moslin, Michael Edward Mertzman, Joseph A. Tino, Shoshana L. Posy, Sirish Kaushik Lakkaraju, Zili Xiao, James Kempson
  • SUBSTITUTED BICYCLIC COMPOUNDS
    Publication number: 20220331346
    Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Application
    Filed: May 4, 2021
    Publication date: October 20, 2022
    Inventors: Alaric J. DYCKMAN, T.G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
  • TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20220119388
    Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
    Type: Application
    Filed: October 18, 2021
    Publication date: April 21, 2022
    Inventors: Guanglin Luo, Jie Chen, Carolyn Diane Dzierba, David B. Frennesson, Junqing Guo, Amy C. Hart, Xirui Hu, Michael C. Mertzman, Matthew Reiser Patton, Jianliang Shi, Steven H. Spergel, Brian Lee Venables, Yong-Jin Wu, Zili Xiao, Michael G. Yang
  • SULFONE PYRIDINE ALKYL AMIDE-SUBSTITUTED HETEROARYL COMPOUNDS
    Publication number: 20210253554
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: April 28, 2021
    Publication date: August 19, 2021
    Inventors: Chunjian Liu, Michael G. Yang, Zili Xiao, Ling Chen, Ryan M. Moslin, John S. Tokarski, David S. Weinstein, Stephen T. Wrobleski
  • Substituted bicyclic compounds
    Patent number: 11058696
    Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: July 13, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, T. G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
  • Sulfone pyridine alkyl amide-substituted heteroaryl compounds
    Patent number: 11021462
    Abstract: Compounds having the following formula I: or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Grant
    Filed: November 20, 2018
    Date of Patent: June 1, 2021
    Assignee: Bristol-Myers Squibb Company
    Inventors: Chunjian Liu, Michael G. Yang, Zili Xiao, Ling Chen, Ryan M. Moslin, John S. Tokarski, David S. Weinstein, Stephen T. Wrobleski
  • HETEROCYCLIC COMPOUNDS COMPRISING PYRIDINE USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES
    Publication number: 20210032220
    Abstract: Compounds having the following formula (I) or a stereoisomer or pharmaceutically-acceptable salt thereof, where R1, R2, R3, R4, and R5 are as defined herein, are useful in the modulation of IL-12, IL-23 and/or IFN?, by acting on Tyk-2 to cause signal transduction inhibition.
    Type: Application
    Filed: March 20, 2019
    Publication date: February 4, 2021
    Inventors: Zili Xiao, Michael G. Yang, Chunjian C. Liu, Trevor C. Sherwood, John L. Gilmore, David S. Weinstein
  • SUBSTITUTED BICYCLIC COMPOUNDS
    Publication number: 20200281952
    Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Application
    Filed: May 21, 2020
    Publication date: September 10, 2020
    Inventors: Alaric J. Dyckman, T.G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
  • Substituted bicyclic compounds
    Patent number: 10709719
    Abstract: Disclosed are compounds of Formulas (I), (II), (III), (IV), and (V): and/or a salt thereof, wherein R1 is —OH or —OP(O)(OH)2, and X1, X2, X3, R2, R2a, Ra, Rb, and Rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: July 14, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: Alaric J. Dyckman, T. G. Murali Dhar, Hai-Yun Xiao, John L. Gilmore, Michael G. Yang, Zili Xiao, David Marcoux
  • Tricyclic sulfone compound as a ROR gamma modulator
    Patent number: 10633339
    Abstract: There is described a ROR? modulator of the formula (I), or stereoisomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof. Also provided are pharmaceutical compositions comprising the same. The compound of the invention may be useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: April 28, 2020
    Assignee: Bristol-Myers Squibb Company
    Inventors: T. G. Murali Dhar, Zili Xiao, Michael G. Yang
  • TRICYCLIC SULFONE COMPOUND AS A ROR GAMMA MODULATOR
    Publication number: 20190352261
    Abstract: There is described a ROR? modulator of the formula (I), or stereoisomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof. Also provided are pharmaceutical compositions comprising the same. The compound of the invention may be useful in methods for modulating ROR? activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of ROR? activity, for example, autoimmune and/or inflammatory disorders.
    Type: Application
    Filed: May 16, 2019
    Publication date: November 21, 2019
    Inventors: T.G. Murali Dhar, Zili Xiao, Michael G. Yang